The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.
Patients eligible for the study, after signing informed consent will be randomized 1:1 for maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy for other classes according to a pre-specified protocol. Patients are going to be followed during hospital stay for evaluation of clinical endpoints. Also blood and urine samples will be acquired for evaluation of renin-angiotensin system activation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
switch anti-hypertensive class
Instituto do Coração - Incor HCFMUSP
São Paulo, São Paulo, Brazil
Need for ICU or mortality
Combined of need for ICU or mortality
Time frame: 30 days
High sensitivity troponin levels and covid-19 severity
Evaluate correlation between hs-TnT and covid-19 severity
Time frame: 30 days
ACE-2 activity and disease severity
Evaluate correlation of ACE-2 activity and disease severity
Time frame: 30 days
ACE-2 activity with different Renin-angiotensin system inhibitors
Evaluate correlation of ACE-2 activity and Renin-angiotensin system inhibitors
Time frame: 30 days
Blood control and acute renal failure
Evaluate blood pressure control and acute renal failure in each arm (safety)
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.